/ TerminatedEarly Phase 1 Proof of Concept Study With an Endothelin Receptor B Inhibitor (BQ-788) for Human Melanoma
Intra-lesion administration of an Endothelin Receptor B inhibitor (BQ-788) or vehicle was preformed in 5 melanoma patients to have a preliminary analysis of safety, dose, duration and relevance of results observed in pre-clinical studies to the human disease.
100 Clinical Results associated with Melcure SA (Switzerland)
0 Patents (Medical) associated with Melcure SA (Switzerland)
100 Deals associated with Melcure SA (Switzerland)
100 Translational Medicine associated with Melcure SA (Switzerland)